EMADOC-1700519818-1975868

European Medicines Agency decision

EMA/PE/0000233122

of 21 March 2025

on the acceptance of a modification of an agreed paediatric investigation plan for fluocinolone acetonide (Iluvien) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000233122

of 21 March 2025

on the acceptance of a modification of an agreed paediatric investigation plan for fluocinolone acetonide (Iluvien) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0156/2017 issued on 8 June 2017 and the decision P/0442/2021 issued on 29 October 2021,

Having regard to the application submitted by Alimera Sciences Limited on 18 October 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 January 2025, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for fluocinolone acetonide (Iluvien), including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Alimera Sciences Limited, Royal Pavilion, Tower 3, Wellesley Road, GU11 1PZ – Aldershot, United Kingdom.

EMADOC-1700519818-1728133
Amsterdam, 31 January 2025

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA/PE/0000233122

Scope of the application

Active substance(s):

Fluocinolone acetonide

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of non-infectious uveitis

Secondary prevention of non-infectious uveitis

Pharmaceutical form(s):

Intravitreal implant in applicator

Route(s) of administration:

Intravitreal use

Name/corporate name of the PIP applicant:

Alimera Sciences Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Alimera Sciences Limited submitted to the European Medicines Agency on 18 October 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0156/2017 issued on 8 June 2017 and the decision P/0442/2021 issued on 29 October 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 25 November 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of non-infectious uveitis

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- intravitreal implant in applicator, intravitreal use;
- on the grounds that the specific medicinal product is likely to be unsafe.

1.2. Condition:

Secondary prevention of non-infectious uveitis

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- intravitreal implant in applicator, intravitreal use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Treatment of non-infectious uveitis

2.1.1. Indication(s) targeted by the PIP

Treatment of and prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye in children from 6 years of age

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Intravitreal implant in applicator

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1** Study deleted within procedure EMEA-000801-PIP03-16-M01
Non-clinical studies	Not applicable

Clinical studies	**Study 2** Open label study to evaluate the safety and efficacy of fluocinolone intravitreal implant in children and adolescents from 6 years to less than 18 years with recurrent non-infectious uveitis affecting the posterior segment of the eye considered insufficiently responsive to, or unsuitable for, the preferred standard of care and thought to require the use of intraocular corticosteroid. (ALI-P01-21-006)
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

2.2. Condition:

Secondary prevention of non-infectious uveitis

2.2.1. Indication(s) targeted by the PIP

Treatment of and prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye in children from 6 years of age

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Intravitreal implant in applicator

2.2.4. Measures

Same as for condition treatment of non-infectious uveitis

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of diabetic macular oedema

Authorised indication(s):

- ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, (DMO) considered insufficiently responsive to available therapies.
  - Invented name(s): ILUVIEN
  - Authorised pharmaceutical form(s): Intravitreal implant in applicator
  - Authorised route(s) of administration: Intravitreal use
  - Authorised via mutual recognition procedure

2. Prevention and Treatment of non-infectious uveitis

Authorised indication(s):

- ILUVIEN is indicated for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
  - Invented name(s): ILUVIEN
  - Authorised pharmaceutical form(s): Intravitreal implant in applicator
  - Authorised route(s) of administration: Intravitreal use
  - Authorised via mutual recognition procedure